Donepezil for the Treatment of Agitation in Alzheimer's Disease
Agitation is common in patients with Alzheimer's disease and is distressing to both patients and their caregivers. In this randomized trial of 272 patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil (5 mg for 4 wee...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2007-10, Vol.357 (14), p.1382-1392 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1392 |
|---|---|
| container_issue | 14 |
| container_start_page | 1382 |
| container_title | The New England journal of medicine |
| container_volume | 357 |
| creator | Howard, Robert J Juszczak, Edmund Ballard, Clive G Bentham, Peter Brown, Richard G Bullock, Roger Burns, Alistair S Holmes, Clive Jacoby, Robin Johnson, Tony Knapp, Martin Lindesay, James O'Brien, John T Wilcock, Gordon Katona, Cornelius Jones, Roy W DeCesare, Julia Rodger, Michaela |
| description | Agitation is common in patients with Alzheimer's disease and is distressing to both patients and their caregivers. In this randomized trial of 272 patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil (5 mg for 4 weeks and 10 mg for 8 weeks) was not more effective than placebo in reducing agitation.
In patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil was not more effective than placebo in reducing agitation.
Alzheimer's disease causes a progressive decline in cognitive and functional ability and distress on the part of both patients and their caregivers. Agitation, a cluster of related symptoms that includes anxiety, irritability, and motor restlessness, leading to behaviors such as pacing, wandering, shouting, and aggression,
1
is seen in 24% of people with Alzheimer's disease who live in the community
2
and in 48% of those living in residential care facilities.
3
Behavioral and psychological symptoms in Alzheimer's disease are distressing to caregivers
4
,
5
and often precipitate the transition to residential care.
6
Atypical neuroleptic agents remain the mainstay of drug treatment despite only . . . |
| doi_str_mv | 10.1056/NEJMoa066583 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223928515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1354055031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c638t-ec2beef1e3bf6b145f84e55313ca74ef35d60a31d6201f2f8cee654c4b9602ae3</originalsourceid><addsrcrecordid>eNpt0D1PwzAQBmALgWgpbMzIQiAWAv5uMqGqLV8qsJQ5ctwzddXExU4H-utJ1Uhl4JZbHr2nexE6p-SOEqnu38evb14TpWTKD1CXSs4TIYg6RF1CWJqIfsY76CTGBWmGiuwYdWg_o4LwrIseRr6CFWzcElsfcD0HPA2g6xKqGnuLB1-u1rXzFXYVHiw3c3AlhJuIRy6CjnCKjqxeRjhrdw99Po6nw-dk8vH0MhxMEqN4WidgWAFgKfDCqoIKaVMBUnLKje4LsFzOFNGczhQj1DKbGgAlhRFFpgjTwHvocpe7Cv57DbHOF34dquZkzhjPWCqbx3vododM8DEGsPkquFKHn5ySfFtW_reshl-0meuihNket-004LoFOhq9tEFXxsW9yyiXhGzd1c6VZcwrWJT_3_sFW9V76A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223928515</pqid></control><display><type>article</type><title>Donepezil for the Treatment of Agitation in Alzheimer's Disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Howard, Robert J ; Juszczak, Edmund ; Ballard, Clive G ; Bentham, Peter ; Brown, Richard G ; Bullock, Roger ; Burns, Alistair S ; Holmes, Clive ; Jacoby, Robin ; Johnson, Tony ; Knapp, Martin ; Lindesay, James ; O'Brien, John T ; Wilcock, Gordon ; Katona, Cornelius ; Jones, Roy W ; DeCesare, Julia ; Rodger, Michaela</creator><creatorcontrib>Howard, Robert J ; Juszczak, Edmund ; Ballard, Clive G ; Bentham, Peter ; Brown, Richard G ; Bullock, Roger ; Burns, Alistair S ; Holmes, Clive ; Jacoby, Robin ; Johnson, Tony ; Knapp, Martin ; Lindesay, James ; O'Brien, John T ; Wilcock, Gordon ; Katona, Cornelius ; Jones, Roy W ; DeCesare, Julia ; Rodger, Michaela ; CALM-AD Trial Group</creatorcontrib><description>Agitation is common in patients with Alzheimer's disease and is distressing to both patients and their caregivers. In this randomized trial of 272 patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil (5 mg for 4 weeks and 10 mg for 8 weeks) was not more effective than placebo in reducing agitation.
In patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil was not more effective than placebo in reducing agitation.
Alzheimer's disease causes a progressive decline in cognitive and functional ability and distress on the part of both patients and their caregivers. Agitation, a cluster of related symptoms that includes anxiety, irritability, and motor restlessness, leading to behaviors such as pacing, wandering, shouting, and aggression,
1
is seen in 24% of people with Alzheimer's disease who live in the community
2
and in 48% of those living in residential care facilities.
3
Behavioral and psychological symptoms in Alzheimer's disease are distressing to caregivers
4
,
5
and often precipitate the transition to residential care.
6
Atypical neuroleptic agents remain the mainstay of drug treatment despite only . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa066583</identifier><identifier>PMID: 17914039</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Addictive behaviors ; Aged ; Aged, 80 and over ; Alzheimer Disease - drug therapy ; Alzheimer Disease - psychology ; Alzheimer's disease ; Behavior ; Biological and medical sciences ; Cholinesterase Inhibitors - adverse effects ; Cholinesterase Inhibitors - therapeutic use ; Confidence intervals ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Double-Blind Method ; Female ; General aspects ; Humans ; Indans - adverse effects ; Indans - therapeutic use ; Male ; Medical sciences ; Neurology ; Older people ; Piperidines - adverse effects ; Piperidines - therapeutic use ; Psychomotor Agitation - drug therapy ; Psychomotor Agitation - etiology ; Psychomotor Agitation - therapy ; Psychotherapy ; Social Support ; Substance abuse treatment ; Treatment Failure</subject><ispartof>The New England journal of medicine, 2007-10, Vol.357 (14), p.1382-1392</ispartof><rights>Copyright © 2007 Massachusetts Medical Society. All rights reserved.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright 2007 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c638t-ec2beef1e3bf6b145f84e55313ca74ef35d60a31d6201f2f8cee654c4b9602ae3</citedby><cites>FETCH-LOGICAL-c638t-ec2beef1e3bf6b145f84e55313ca74ef35d60a31d6201f2f8cee654c4b9602ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa066583$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223928515?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19135009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17914039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Howard, Robert J</creatorcontrib><creatorcontrib>Juszczak, Edmund</creatorcontrib><creatorcontrib>Ballard, Clive G</creatorcontrib><creatorcontrib>Bentham, Peter</creatorcontrib><creatorcontrib>Brown, Richard G</creatorcontrib><creatorcontrib>Bullock, Roger</creatorcontrib><creatorcontrib>Burns, Alistair S</creatorcontrib><creatorcontrib>Holmes, Clive</creatorcontrib><creatorcontrib>Jacoby, Robin</creatorcontrib><creatorcontrib>Johnson, Tony</creatorcontrib><creatorcontrib>Knapp, Martin</creatorcontrib><creatorcontrib>Lindesay, James</creatorcontrib><creatorcontrib>O'Brien, John T</creatorcontrib><creatorcontrib>Wilcock, Gordon</creatorcontrib><creatorcontrib>Katona, Cornelius</creatorcontrib><creatorcontrib>Jones, Roy W</creatorcontrib><creatorcontrib>DeCesare, Julia</creatorcontrib><creatorcontrib>Rodger, Michaela</creatorcontrib><creatorcontrib>CALM-AD Trial Group</creatorcontrib><title>Donepezil for the Treatment of Agitation in Alzheimer's Disease</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Agitation is common in patients with Alzheimer's disease and is distressing to both patients and their caregivers. In this randomized trial of 272 patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil (5 mg for 4 weeks and 10 mg for 8 weeks) was not more effective than placebo in reducing agitation.
In patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil was not more effective than placebo in reducing agitation.
Alzheimer's disease causes a progressive decline in cognitive and functional ability and distress on the part of both patients and their caregivers. Agitation, a cluster of related symptoms that includes anxiety, irritability, and motor restlessness, leading to behaviors such as pacing, wandering, shouting, and aggression,
1
is seen in 24% of people with Alzheimer's disease who live in the community
2
and in 48% of those living in residential care facilities.
3
Behavioral and psychological symptoms in Alzheimer's disease are distressing to caregivers
4
,
5
and often precipitate the transition to residential care.
6
Atypical neuroleptic agents remain the mainstay of drug treatment despite only . . .</description><subject>Addictive behaviors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Behavior</subject><subject>Biological and medical sciences</subject><subject>Cholinesterase Inhibitors - adverse effects</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Confidence intervals</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Indans - adverse effects</subject><subject>Indans - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Older people</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - therapeutic use</subject><subject>Psychomotor Agitation - drug therapy</subject><subject>Psychomotor Agitation - etiology</subject><subject>Psychomotor Agitation - therapy</subject><subject>Psychotherapy</subject><subject>Social Support</subject><subject>Substance abuse treatment</subject><subject>Treatment Failure</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0D1PwzAQBmALgWgpbMzIQiAWAv5uMqGqLV8qsJQ5ctwzddXExU4H-utJ1Uhl4JZbHr2nexE6p-SOEqnu38evb14TpWTKD1CXSs4TIYg6RF1CWJqIfsY76CTGBWmGiuwYdWg_o4LwrIseRr6CFWzcElsfcD0HPA2g6xKqGnuLB1-u1rXzFXYVHiw3c3AlhJuIRy6CjnCKjqxeRjhrdw99Po6nw-dk8vH0MhxMEqN4WidgWAFgKfDCqoIKaVMBUnLKje4LsFzOFNGczhQj1DKbGgAlhRFFpgjTwHvocpe7Cv57DbHOF34dquZkzhjPWCqbx3vododM8DEGsPkquFKHn5ySfFtW_reshl-0meuihNket-004LoFOhq9tEFXxsW9yyiXhGzd1c6VZcwrWJT_3_sFW9V76A</recordid><startdate>20071004</startdate><enddate>20071004</enddate><creator>Howard, Robert J</creator><creator>Juszczak, Edmund</creator><creator>Ballard, Clive G</creator><creator>Bentham, Peter</creator><creator>Brown, Richard G</creator><creator>Bullock, Roger</creator><creator>Burns, Alistair S</creator><creator>Holmes, Clive</creator><creator>Jacoby, Robin</creator><creator>Johnson, Tony</creator><creator>Knapp, Martin</creator><creator>Lindesay, James</creator><creator>O'Brien, John T</creator><creator>Wilcock, Gordon</creator><creator>Katona, Cornelius</creator><creator>Jones, Roy W</creator><creator>DeCesare, Julia</creator><creator>Rodger, Michaela</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20071004</creationdate><title>Donepezil for the Treatment of Agitation in Alzheimer's Disease</title><author>Howard, Robert J ; Juszczak, Edmund ; Ballard, Clive G ; Bentham, Peter ; Brown, Richard G ; Bullock, Roger ; Burns, Alistair S ; Holmes, Clive ; Jacoby, Robin ; Johnson, Tony ; Knapp, Martin ; Lindesay, James ; O'Brien, John T ; Wilcock, Gordon ; Katona, Cornelius ; Jones, Roy W ; DeCesare, Julia ; Rodger, Michaela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c638t-ec2beef1e3bf6b145f84e55313ca74ef35d60a31d6201f2f8cee654c4b9602ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Addictive behaviors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Behavior</topic><topic>Biological and medical sciences</topic><topic>Cholinesterase Inhibitors - adverse effects</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Confidence intervals</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Indans - adverse effects</topic><topic>Indans - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Older people</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - therapeutic use</topic><topic>Psychomotor Agitation - drug therapy</topic><topic>Psychomotor Agitation - etiology</topic><topic>Psychomotor Agitation - therapy</topic><topic>Psychotherapy</topic><topic>Social Support</topic><topic>Substance abuse treatment</topic><topic>Treatment Failure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Howard, Robert J</creatorcontrib><creatorcontrib>Juszczak, Edmund</creatorcontrib><creatorcontrib>Ballard, Clive G</creatorcontrib><creatorcontrib>Bentham, Peter</creatorcontrib><creatorcontrib>Brown, Richard G</creatorcontrib><creatorcontrib>Bullock, Roger</creatorcontrib><creatorcontrib>Burns, Alistair S</creatorcontrib><creatorcontrib>Holmes, Clive</creatorcontrib><creatorcontrib>Jacoby, Robin</creatorcontrib><creatorcontrib>Johnson, Tony</creatorcontrib><creatorcontrib>Knapp, Martin</creatorcontrib><creatorcontrib>Lindesay, James</creatorcontrib><creatorcontrib>O'Brien, John T</creatorcontrib><creatorcontrib>Wilcock, Gordon</creatorcontrib><creatorcontrib>Katona, Cornelius</creatorcontrib><creatorcontrib>Jones, Roy W</creatorcontrib><creatorcontrib>DeCesare, Julia</creatorcontrib><creatorcontrib>Rodger, Michaela</creatorcontrib><creatorcontrib>CALM-AD Trial Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Howard, Robert J</au><au>Juszczak, Edmund</au><au>Ballard, Clive G</au><au>Bentham, Peter</au><au>Brown, Richard G</au><au>Bullock, Roger</au><au>Burns, Alistair S</au><au>Holmes, Clive</au><au>Jacoby, Robin</au><au>Johnson, Tony</au><au>Knapp, Martin</au><au>Lindesay, James</au><au>O'Brien, John T</au><au>Wilcock, Gordon</au><au>Katona, Cornelius</au><au>Jones, Roy W</au><au>DeCesare, Julia</au><au>Rodger, Michaela</au><aucorp>CALM-AD Trial Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Donepezil for the Treatment of Agitation in Alzheimer's Disease</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2007-10-04</date><risdate>2007</risdate><volume>357</volume><issue>14</issue><spage>1382</spage><epage>1392</epage><pages>1382-1392</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Agitation is common in patients with Alzheimer's disease and is distressing to both patients and their caregivers. In this randomized trial of 272 patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil (5 mg for 4 weeks and 10 mg for 8 weeks) was not more effective than placebo in reducing agitation.
In patients with Alzheimer's disease who had agitated behavior that did not respond to a psychosocial treatment program, donepezil was not more effective than placebo in reducing agitation.
Alzheimer's disease causes a progressive decline in cognitive and functional ability and distress on the part of both patients and their caregivers. Agitation, a cluster of related symptoms that includes anxiety, irritability, and motor restlessness, leading to behaviors such as pacing, wandering, shouting, and aggression,
1
is seen in 24% of people with Alzheimer's disease who live in the community
2
and in 48% of those living in residential care facilities.
3
Behavioral and psychological symptoms in Alzheimer's disease are distressing to caregivers
4
,
5
and often precipitate the transition to residential care.
6
Atypical neuroleptic agents remain the mainstay of drug treatment despite only . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>17914039</pmid><doi>10.1056/NEJMoa066583</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2007-10, Vol.357 (14), p.1382-1392 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223928515 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Addictive behaviors Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - psychology Alzheimer's disease Behavior Biological and medical sciences Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - therapeutic use Confidence intervals Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Double-Blind Method Female General aspects Humans Indans - adverse effects Indans - therapeutic use Male Medical sciences Neurology Older people Piperidines - adverse effects Piperidines - therapeutic use Psychomotor Agitation - drug therapy Psychomotor Agitation - etiology Psychomotor Agitation - therapy Psychotherapy Social Support Substance abuse treatment Treatment Failure |
| title | Donepezil for the Treatment of Agitation in Alzheimer's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Donepezil%20for%20the%20Treatment%20of%20Agitation%20in%20Alzheimer's%20Disease&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Howard,%20Robert%20J&rft.aucorp=CALM-AD%20Trial%20Group&rft.date=2007-10-04&rft.volume=357&rft.issue=14&rft.spage=1382&rft.epage=1392&rft.pages=1382-1392&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa066583&rft_dat=%3Cproquest_cross%3E1354055031%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223928515&rft_id=info:pmid/17914039&rfr_iscdi=true |